Want to see JP:4570 full AI Analyst Report?
Top Page
Immuno-Biological Laboratories Co., Ltd.
(4570)
Select Model
Select Model
Rating:71Outperform
Price Target:
¥1,213.00
▼(-13.60% Downside)
Action:Upgraded
Date:08/21/26
The score is primarily supported by improved financial performance (strong recent profitability, strengthening balance sheet, and renewed free-cash-flow generation). Technicals add moderate support via positive momentum signals, but the longer-term downtrend versus the 100/200-day averages is a meaningful offset. Valuation further tempers the result due to a higher P/E and minimal dividend yield.
Positive Factors
Strong profitability turnaround
The return to strong operating and net profitability indicates improved earnings capacity and potentially better business execution. Sustaining these margins would provide resources for product development, commercial investment, and resilience across the next several quarters.
Negative Factors
High historical earnings volatility
The recent turnaround has not yet demonstrated a long, stable record of profitability. Earlier deep losses increase uncertainty about the durability of margins and earnings, particularly if research demand, product mix, or operating conditions weaken.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong profitability turnaround
The return to strong operating and net profitability indicates improved earnings capacity and potentially better business execution. Sustaining these margins would provide resources for product development, commercial investment, and resilience across the next several quarters.
Read all positive factors
Immuno-Biological Laboratories Co., Ltd. (4570) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.79B
Dividend Yield0.55%
Average Volume (3M)23.51K
Price to Earnings (P/E)27.5
Beta (1Y)0.97
Revenue Growth13.46%
EPS Growth42.41%
CountryJP
Employees54
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)39.54
Shares Outstanding9,314,590
10 Day Avg. Volume28,690
30 Day Avg. Volume23,506
Financial Highlights & Ratios
PEG Ratio1.18
Price to Book (P/B)6.78
Price to Sales (P/S)12.44
P/FCF Ratio46.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Immuno-Biological Laboratories Co., Ltd. Business Overview & Revenue Model
Company Description
Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise qua...
How the Company Makes Money
Immuno-Biological Laboratories Co., Ltd. makes money primarily by selling life-science reagents and related research-use products to customers such as academic laboratories, research institutes, and private-sector R&D organizations. Key revenue st...
Immuno-Biological Laboratories Co., Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.08B | 1.00B | 969.53M | 816.70M | 794.62M | 647.58M |
| Gross Profit | 777.51M | 700.28M | 628.34M | 517.29M | 526.71M | 376.70M |
| EBITDA | 368.36M | 299.82M | 226.55M | 128.11M | -279.54M | -249.50M |
| Net Income | 368.32M | 329.01M | 249.05M | 186.69M | -289.73M | -258.77M |
Balance Sheet | ||||||
| Total Assets | 2.23B | 2.16B | 1.85B | 1.62B | 1.43B | 1.71B |
| Cash, Cash Equivalents and Short-Term Investments | 907.94M | 989.47M | 825.73M | 734.14M | 614.16M | 508.35M |
| Total Debt | 171.81M | 177.09M | 204.23M | 235.98M | 234.99M | 234.00M |
| Total Liabilities | 338.30M | 311.75M | 332.03M | 354.25M | 355.72M | 336.99M |
| Stockholders Equity | 1.89B | 1.84B | 1.51B | 1.27B | 1.08B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 267.68M | 123.83M | 115.11M | 26.46M | -93.20M |
| Operating Cash Flow | 0.00 | 301.09M | 183.50M | 133.78M | 26.46M | -93.20M |
| Investing Cash Flow | 0.00 | -116.46M | -53.66M | -24.50M | 30.04M | -155.63M |
| Financing Cash Flow | 0.00 | -27.14M | -31.75M | 991.00K | 991.00K | 144.00M |
Immuno-Biological Laboratories Co., Ltd. Technical Analysis
Positive
1404.00
Price Trends
986.80
Positive
1120.02
Negative
1323.33
Negative
Market Momentum
25.99
Negative
60.22
Neutral
54.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4570, the sentiment is Positive. The current price of 1404 is above the 20-day moving average (MA) of 1010.20, above the 50-day MA of 986.80, and above the 200-day MA of 1323.33, indicating a neutral trend. The MACD of 25.99 indicates Negative momentum. The RSI at 60.22 is Neutral, neither overbought nor oversold. The STOCH value of 54.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4570.
Immuno-Biological Laboratories Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥9.79B | 27.52 | ― | ― | 13.46% | 42.41% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ¥35.25B | -78.23 | ― | ― | 3.43% | -53.59% | |
51 Neutral | ¥22.00B | -11.71 | ― | ― | ― | 6.10% | |
45 Neutral | ¥15.05B | -32.46 | ― | ― | -18.71% | -246.54% | |
42 Neutral | ¥9.23B | -7.98 | ― | ― | -56.16% | 3.12% |
* General Sector Average
JP:4570
Immuno-Biological Laboratories Co., Ltd.
1,088.00
611.05
128.11%
JP:4599
StemRIM Inc.
351.00
46.00
15.08%
JP:4978
ReproCELL Inc.
149.00
-29.00
-16.29%
JP:7774
Japan Tissue Engineering Co., Ltd.
848.00
364.00
75.21%
JP:7776
CellSeed Inc.
231.00
-210.00
-47.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.